In the early days of the pandemic, the federal government announced a multi-million-dollar funding agreement with the National Research Council (NRC) to expand a vaccine facility in Montreal — a site Prime Minister Justin Trudeau said would pump out Canadian-made COVID-19 shots by November 2020.
Two years after the prime minister made that pledge, the NRC facility still hasn’t produced a single vial of a COVID-19 vaccine.
A spokesperson for the NRC, the federal entity dedicated to research and development, told CBC News its vaccine facility recently secured the necessary Health Canada approvals. But the NRC still offered no target date for when the biologics manufacturing centre (BMC) will be operational.
“The inspection by Health Canada took place in late July 2022 and the facility has been rated as compliant,” the NRC spokesperson said.
Prime Minister Justin Trudeau, right, speaks with scientist Krishnaraj Tiwari during a visit to the National Research Council of Canada (NRC) Royalmount Human Health Therapeutics Research Centre facility in Montreal, Monday, Aug 31, 2020. The site was supposed to start pumping out COVID-19 vaccine doses by the end of 2021. (Graham Hughes/Canadian Press)
The spokesperson referred questions about vaccine production to Novavax, the Maryland-based company that was tapped by Ottawa to make COVID-19 shots at the facility.
In a statement, a spokesperson for Novavax said the company “continues to work with the NRC to complete the tech transfer of our COVID-19 vaccine” and it anticipates “integrating supply from this facility into our vaccine program” at an unspecified later date.
While announcing a $44-million investment for the NRC facility in April 2020, Trudeau said expanding this site and others would put Canada “at the forefront of scientific research” and give the country the “infrastructure to prepare vials for individual doses as soon as a vaccine becomes available.”
In August of that year, the government pumped an additional $126 million into the NRC’s Royalmount site, a federal investment that Trudeau said would “enable the preliminary production of 250,000 doses of vaccine per month starting in November 2020.”
In August 2020, Prime Minister Justin Trudeau said the National Research Council (NRC)’S Royalmount facility would be producing shots by mid-2021. Two years after that promise, the site hasn’t produced a single vial of a COVID-19 vaccine. (Graham Hughes/Canadian Press)
But when November 2020 came, Trudeau conceded there wouldn’t be any shots rolling off the line as planned. The project’s initial timeline was derailed by construction delays and a failed deal with a Chinese vaccine maker.
In February 2021, as Canada was grappling with limited vaccine supply, Trudeau claimed that the NRC’s facility would finish construction sometime that summer — and that shots would soon follow.
“We expect the facility to be up and running by mid-2021,” Trudeau said.
In an interview with CBC News at the time, Industry Minister François-Philippe Champagne compared building this sort of facility from the ground up on such a constrained timeline to the U.S. mission to put a man on the moon.
“This is like the Apollo project,” Champagne said. “Normally, it would take two to three years to do this, to get a production facility up and running.”
WATCH: Industry minister said production of COVID-19 vaccines would start in 2021
Minister says production of COVID-19 vaccines will begin in Canada later this year
2 years ago
Duration 2:42
Minister of Innovation, Science and Industry François-Philippe Champagne said he expected production of the doses to begin at the Montreal-based plant in 2021.
With Pfizer and Moderna facing insatiable demand for their products at this early stage of the immunization campaign, Trudeau’s announcement and Champagne’s optimism were welcome news for Canadians concerned about a dearth of shots.
Asked to comment Friday, Champagne’s office said he wasn’t available for an interview.
Trudeau also announced in February 2021 the government’s partnership with Novavax, a company that, before COVID-19, had never actually brought a vaccine to market.
This U.S. outfit, Trudeau said, would churn out tens of millions of its shots at the Montreal site. “This is a major step forward to get vaccines made in Canada, for Canadians,” he said.
WATCH: In 2021, Trudeau is questioned about Novavax COVID-19 vaccine deal
Trudeau questioned over Novavax COVID-19 vaccine deal
2 years ago
Duration 2:55
Prime Minister Justin Trudeau is asked how starting production of the Novavax vaccine will affect his government’s vaccination goals.
Dr. Earl Brown is a professor emeritus at the University of Ottawa’s school of medicine and an expert in virology and microbiology. He said the government’s timeline for starting production was “completely unrealistic.”
“These things are just really complicated to build. There’s just so much regulation — it’s extreme. So I think it was crazily optimistic,” he said.
“You need two years, at a minimum, to build any new facility. I didn’t believe any of those numbers when I first heard them.”
Brown said another major vaccine production project in Canada — a $925-million expansion of French pharmaceutical giant Sanofi’s Toronto campus — has a five-year timeline, with production expected to start sometime in 2027.
An optimistic timeline
“The leading vaccine producer in the world gave themselves five years and they do this all the time,” Brown said, adding that the government should have anticipated that a relatively untested company like Novavax would need more time.
Once a world-leader in vaccine development and production, Canada’s manufacturing capability has been hollowed out after decades of cuts and mismanagement. The government has said little lately about the NRC facility it once touted as a solution to the country’s vaccine woes.
The NRC quietly announced in June 2021 that the site had finished construction on time — an impressive achievement that came just ten months after the first shovels hit the ground.
But in the world of biomanufacturing, construction is just one of many hurdles an entity must clear before it can start churning out sensitive products like a COVID-19 vaccine or another therapeutic.
Such a company must satisfy a series of industry and regulatory requirements before vaccines or biologics can be manufactured safely.
‘Were they too ambitious?’
Marc-André Gagnon, an associate professor at Carleton University and an expert on the pharmaceutical industry, said the government made its promise to build the NRC site during an “emergency situation” and the 2021 production start date was likely its best-case scenario.
“They had to be ambitious. The question is, were they too ambitious? Some voices say that they were. We didn’t know in 2020 when vaccines would be available but we probably knew that a facility like this wouldn’t be ready before the end of 2021, for sure,” he told CBC News.
Gagnon said that, despite the delays, Royalmount is a welcome addition to Canada’s manufacturing landscape. He said a developed country like Canada needs a publicly owned — and domestic — source of vaccines to avoid the mad scramble that defined the early COVID-19 vaccine procurement process.
“Canada used to be a hub for vaccine manufacturing. We were world-class. We need biomanufacturing capacity for the next thing, the next pandemic,” he said.
“And let me emphasize this — we need more public manufacturing capacity to discipline the private market a little bit and avoid predatory pricing.”
The NDP’s Don Davies says the Trudeau government has a “serious credibility issue” on vaccine production. (Ian Christie/CBC)
NDP MP Don Davies, the party’s health critic, agreed that some sort of public option for vaccine production is prudent but the government’s handling of the NRC facility has been “a major failure.”
He said it suggests Ottawa has a “serious credibility issue.”
“We are two years plus into this pandemic and we still aren’t producing a single dose of a vaccine in this country. It’s a policy fail, an accountability fail and a credibility fail,” he said in an interview with CBC News.
“The prime minister said publicly in August 2020 that we’d be producing vaccines at the Montreal facility. That was either highly irresponsible, or incompetent, or it was deceptive. I don’t know which of the three it is but Canadians know — we had a direct, clear promise from the prime minister about vaccines being produced here in Canada at a time when we were all on pins and needles.
“He was either misinformed or he was misleading. He has a duty to come clean with Canadians.”
Conservative MP Michael Barrett, the party’s health critic, was equally scathing in his assessment of the government’s vaccine track record.
In a statement, Barrett said the “Trudeau Liberals spent millions of dollars on their promises to produce vaccines domestically, and after two years they have missed every deadline with nothing to show for it.”
WINNIPEG – Some 250 coloured tacks pepper a large-scale world map among bookshelves at Whodunit Mystery Bookstore.
Estonia, Finland, Japan and even Fenwick, Ont., have pins representing places outside Winnipeg where someone has ordered a page-turner from the independent bookstore that specializes in mystery and crime fiction novels.
For 30 years, the store has been offering fans of Agatha Christie’s Hercule Poirot or Arthur Conan Doyle’s Sherlock Holmes a place to get lost in whodunits both old and new.
Jack and Wendy Bumsted bought the shop in the Crescentwood neighbourhood in 2007 from another pair of mystery lovers.
The married couple had been longtime customers of the store. Wendy Bumsted grew up reading Perry Mason novels while her husband was a historian with vast knowledge of the crime fiction genre.
At the time, Jack Bumsted was retiring from teaching at the University of Manitoba when he was looking for his next venture.
“The bookstore came up and we bought it, I think, within a week,” Wendy Bumsted said in an interview.
“It never didn’t seem like a good idea.”
In the years since the Bumsteds took ownership, the family has witnessed the decline in mail-order books, the introduction of online retailers, a relocation to a new space next to the original, a pandemic and the death of beloved co-owner Jack Bumsted in 2020.
But with all the changes that come with owning a small business, customers continue to trust their next mystery fix will come from one of the shelves at Whodunit.
Many still request to be called about books from specific authors, or want to be notified if a new book follows their favourite format. Some arrive at the shop like clockwork each week hoping to get suggestions from Wendy Bumsted or her son on the next big hit.
“She has really excellent instincts on what we should be getting and what we should be promoting,” Micheal Bumsted said of his mother.
Wendy Bumsted suggested the store stock “Thursday Murder Club,” the debut novel from British television host Richard Osman, before it became a bestseller. They ordered more copies than other bookstores in Canada knowing it had the potential to be a hit, said Michael Bumsted.
The store houses more than 18,000 new and used novels. That’s not including the boxes of books that sit in Wendy Bumsted’s tiny office, or the packages that take up space on some of the only available seating there, waiting to be added to the inventory.
Just as the genre has evolved, so has the Bumsteds’ willingness to welcome other subjects on their shelves — despite some pushback from loyal customers and initially the Bumsted patriarch.
For years, Jack Bumsted refused to sell anything outside the crime fiction genre, including his own published books. Instead, he would send potential buyers to another store, but would offer to sign the books if they came back with them.
Wendy Bumsted said that eventually changed in his later years.
Now, about 15 per cent of the store’s stock is of other genres, such as romance or children’s books.
The COVID-19 pandemic forced them to look at expanding their selection, as some customers turned to buying books through the store’s website, which is set up to allow purchasers to get anything from the publishers the Bumsteds have contracts with.
In 2019, the store sold fewer than 100 books online. That number jumped to more than 3,000 in 2020, as retailers had to deal with pandemic lockdowns.
After years of running a successful mail-order business, the store was able to quickly adapt when it had to temporarily shut its doors, said Michael Bumsted.
“We were not a store…that had to figure out how to get books to people when they weren’t here.”
He added being a community bookstore with a niche has helped the family stay in business when other retailers have struggled. Part of that has included building lasting relationships.
“Some people have put it in their wills that their books will come to us,” said Wendy Bumsted.
Some of those collections have included tips on traveling through Asia in the early 2000s or the history of Australian cricket.
Micheal Bumsted said they’ve had to learn to be patient with selling some of these more obscure titles, but eventually the time comes for them to find a new home.
“One of the great things about physical books is that they can be there for you when you are ready for them.”
This report by The Canadian Press was first published on Sept. 15, 2024.
MONTREAL – Canada’s labour minister is praising both Air Canada and the union representing about 5,200 of its pilots for averting a work stoppage that would have disrupted travel for hundreds of thousands of passengers.
Steven MacKinnon’s comments came in a statement shared to social media shortly after Canada’s largest air carrier announced it had reached a tentative labour deal with the Air Line Pilots Association.
MacKinnon thanked both sides and federal mediators, saying the airline and its pilots approached negotiations with “seriousness and a resolve to get a deal.”
The tentative agreement averts a strike or lockout that could have begun as early as Wednesday for Air Canada and Air Canada Rouge, with flight cancellations expected before then.
The airline now says flights will continue as normal while union members vote on the tentative four-year contract.
Air Canada had called on the federal government to intervene in the dispute, but Prime Minister Justin Trudeau said Friday that would only happen if it became clear no negotiated agreement was possible.
This report from The Canadian Press was first published Sept. 15, 2024.
When it comes to plant-based alternatives, Canadians have never had so many options — and nowhere is that choice more abundantly clear than in the milk section of the dairy aisle.
To meet growing demand, companies are investing in new products and technology to keep up with consumer tastes and differentiate themselves from all the other players on the shelf.
“The product mix has just expanded so fast,” said Liza Amlani, co-founder of the Retail Strategy Group.
She said younger generations in particular are driving growth in the plant-based market as they are consuming less dairy and meat.
Commercial sales of dairy milk have been weakening for years, according to research firm Mintel, likely in part because of the rise of plant-based alternatives — even though many Canadians still drink dairy.
The No. 1 reason people opt for plant-based milk is because they see it as healthier than dairy, said Joel Gregoire, Mintel’s associate director for food and drink.
“Plant-based milk, the one thing about it — it’s not new. It’s been around for quite some time. It’s pretty established,” said Gregoire.
Because of that, it serves as an “entry point” for many consumers interested in plant-based alternatives to animal products, he said.
Plant-based milk consumption is expected to continue growing in the coming years, according to Mintel research, with more options available than ever and more consumers opting for a diet that includes both dairy and non-dairy milk.
A 2023 report by Ernst & Young for Protein Industries Canada projected that the plant-based dairy market will reach US$51.3 billion in 2035, at a compound annual growth rate of 9.5 per cent.
Because of this growth opportunity, even well-established dairy or plant-based companies are stepping up their game.
It’s been more than three decades since Saint-Hyacinthe, Que.-based Natura first launched a line of soy beverages. Over the years, the company has rolled out new products to meet rising demand, and earlier this year launched a line of oat beverages that it says are the only ones with a stamp of approval from Celiac Canada.
Competition is tough, said owner and founder Nick Feldman — especially from large American brands, which have the money to ensure their products hit shelves across the country.
Natura has kept growing, though, with a focus on using organic ingredients and localized production from raw materials.
“We’re maybe not appealing to the mass market, but we’re appealing to the natural consumer, to the organic consumer,” Feldman said.
Amlani said brands are increasingly advertising the simplicity of their ingredient lists. She’s also noticing more companies offering different kinds of products, such as coffee creamers.
Companies are also looking to stand out through eye-catching packaging and marketing, added Amlani, and by competing on price.
Besides all the companies competing for shelf space, there are many different kinds of plant-based milk consumers can choose from, such as almond, soy, oat, rice, hazelnut, macadamia, pea, coconut and hemp.
However, one alternative in particular has enjoyed a recent, rapid ascendance in popularity.
“I would say oat is the big up-and-coming product,” said Feldman.
Mintel’s report found the share of Canadians who say they buy oat milk has quadrupled between 2019 and 2023 (though almond is still the most popular).
“There seems to be a very nice marriage of coffee and oat milk,” said Feldman. “The flavour combination is excellent, better than any other non-dairy alternative.”
The beverage’s surge in popularity in cafés is a big part of why it’s ascending so quickly, said Gregoire — its texture and ability to froth makes it a good alternative for lattes and cappuccinos.
It’s also a good example of companies making a strong “use case” for yet another new entrant in a competitive market, he said.
Amid the long-standing brands and new entrants, there’s another — perhaps unexpected — group of players that has been increasingly investing in plant-based milk alternatives: dairy companies.
For example, Danone has owned the Silk and So Delicious brands since an acquisition in 2014, and long-standing U.S. dairy company HP Hood LLC launched Planet Oat in 2018.
Lactalis Canada also recently converted its facility in Sudbury, Ont., to manufacture its new plant-based Enjoy! brand, with beverages made from oats, almonds and hazelnuts.
“As an organization, we obviously follow consumer trends, and have seen the amount of interest in plant-based products, particularly fluid beverages,” said Mark Taylor, president and CEO of Lactalis Canada, whose parent company Lactalis is the largest dairy products company in the world.
The facility was a milk processing plant for six decades, until Lactalis Canada began renovating it in 2022. It now manufactures not only the new brand, but also the company’s existing Sensational Soy brand, and is the company’s first dedicated plant-based facility.
“We’re predominantly a dairy company, and we’ll always predominantly be a dairy company, but we see these products as complementary,” said Taylor.
It makes sense that major dairy companies want to get in on plant-based milk, said Gregoire. The dairy business is large — a “cash cow,” if you will — but not really growing, while plant-based products are seeing a boom.
“If I’m looking for avenues of growth, I don’t want to be left behind,” he said.
Gregoire said there’s a potential for consumers to get confused with so many options, which is why it’s so important for brands to find a way to differentiate themselves, whether it’s with taste, health, or how well the drink froths for a latte.
Competition in a more crowded market is challenging, but Taylor believes it results in better products for consumers.
“It keeps you sharp, and it forces you to be really good at what you’re doing. It drives innovation,” he said.
This report by The Canadian Press was first published Sept. 15, 2024.
